feldman 20 february 20031 pilot plant through scale-up manufacturing martha a. feldman, rac drug...
TRANSCRIPT
Feldman 20 February 2003
1
Pilot Plant through Scale-Up Manufacturing
Martha A. Feldman, RACDrug & Device Development Co., Inc.P.O. Box 3515 Redmond, WA 98073-3515 USA1-425-861-8262 FAX: [email protected]
Feldman 20 February 2003
2
Pilot Plant
• Needed to make supplies for– bench studies,
• product characterization, purity
– animal studies• toxicology• pharmacokinetics, ADME• efficacy
– clinical studies
Feldman 20 February 2003
3
Regulations
• Code of Federal Regulations Title 21– Part 210 and 211 - Good Manufacturing
Practices for Drugs– Part 600 - 680 Processing of Biological
materials– Part 820 - Quality System Regulations
for Medical Devices• Subpart C: Design Controls
Feldman 20 February 2003
4
Initial Manufacturing Stages
• Goals:– increasing compliance with regulations
as product moves through testing and evaluation
– increasing knowledge about the product– increasing knowledge about the
possible problems, snags, pitfalls with manufacturing, processing, packing, storing (and installing) the product
Feldman 20 February 2003
5
Drugs and Biologics
Feldman 20 February 2003
6
Clinical Trials Supplies for Drugs and Biologics -1
• Prior to phase I: need product safety testing and basic characterization information, cell bank characterization
• Phase I/II: requires completed safety profile and further characterization of the product (stress testing), process controls, assay descriptions, beginning specifications or limits
Feldman 20 February 2003
7
Clinical Trials Supplies for Drugs and Biologics -2
• Phase III requires full characterization:– Impurities profiles– Specifications: Identity, Potency, Purity, Safety– Raw materials testing– Stability testing Process Validation– Container/closure Analytical Validation– Process controls Equipment Validation– Batch records Facility Validation
– Yield expectations
Feldman 20 February 2003
8
Good Manufacturing Practices 1
• Part 210 – Current GMPs in manufacturing,
processing, packing or holding of drugs
• Part 211– Current GMPs for finished
pharmaceuticals– Ten major areas
Feldman 20 February 2003
9
Good Manufacturing Practices 2
• Organization and Personnel• Buildings and Facilities• Equipment• Control of components and drug product containers and
closures• Production and process controls• Packaging and labeling control• Holding and distribution• Laboratory Controls• Records and reports• Returned and salvaged drug products
Feldman 20 February 2003
10
Good Manufacturing Practices 3
• When regulations in Parts 600-680 (biologics) are in conflict with these regulations, the ones most closely pertaining to the drug product will supersede.
• This regulation may not be applicable to OTC products that are ordinarily marketed and consumed as human food.
Feldman 20 February 2003
11
Biologics Manufacturing (21 CFR Parts 600-680)
• Current GMPs for blood and blood components• General biological products standards• General requirements for blood, blood
components and blood derivatives• Additional standards for human blood and blood
products• Additional standards for diagnostic substances
for laboratory tests• Additional standards for miscellaneous products
Feldman 20 February 2003
12
Medical Devices
Feldman 20 February 2003
13
Initial Development - 1
• Must follow Design Controls from the outset (Design Controls for Medical Device Manufacturers [Mar 1997] http://www.fda.gov/cdrh/comp/designgd.html
• Must develop or use validated tests to determine– operating conditions, e.g., temperature, humidity, altitude
limits– reliability– durability; robustness– stability; shelf life– biocompatibility– ergonomics, e.g., ease of use
Feldman 20 February 2003
14
Initial Development - 2
– sterility– electromagnetic compatibility– radio frequency interference– electromagnetic compatibility– radio frequency interference– electrical leakage– power output– material strength, flexibility, durability, etc.
Feldman 20 February 2003
15
Initial Development - 3
• Must develop vendor qualifications• If using contract manufacturer, should
obtain prior Inspection Reports (483s), do an independent audit
• Must develop training program for others, e.g., receptionist (regarding calls on complaints, visits by FDA inspectors), customer service (re: complaints), etc.
Feldman 20 February 2003
16
Clinical Trial Supplies for Medical Devices -1
• Device must meet Design Controls– Design input and output– Design review– Verification and validation
• If changes occur during clinical study– Simple modifications:
• Clarify Instructions For Use• Annual Report (812.150)• 5-Day Notice (812.35)
Feldman 20 February 2003
17
Clinical Trial Supplies for Medical Devices - 2
– Significant changes• Modification to study design or device material• IDE Supplement requiring approval (812.35)
• Who decides what to submit?– Decision on which type of submission is
manufacturer’s responsibility– Decision is based on
• Range of minor to significant• Type of device• Type of modification
Feldman 20 February 2003
18
Clinical Trial Supplies for Medical Devices - 3
• Credible information (812.35)– Used to support developmental changes
in the device (including manufacturing changes)
– Includes data generated under • design control procedures • preclinical/animal testing • FDA-issued testing (e.g., guidance)• peer reviewed published literature• other reliable information (e.g., clinical data)
Feldman 20 February 2003
19
Quality System Regulation 1(21 CFR Part 820)
• QS Requirements - management responsibility
• Design Controls• Document Controls• Identification and Traceability• Production and Process Controls• Acceptance Activities• Nonconforming Product
Feldman 20 February 2003
20
Quality System Regulation 2
• Corrective and Preventive Action• Labeling and Packaging Control• Handling, Storage, Distribution
and Installation• Records• Servicing• Statistical Techniques
Feldman 20 February 2003
21
Software-driven Medical Devices
• Software verification, validation and testing required• Must look at integration as features or modules are
added• Guidance documents:
– General principles of software validation, Guidance for Industry and FDA http://www.fda.gov/cdrh/comp/guidance/938.html (Jan 11, 2002)
– Off-the-Shelf Software use in medical devices http://www.fda.gov/cdrh/ode/guidance/585.html (Sep 9, 1999)
– Content of Premarket Submissions for software contained in medical devices http://www.fda.gov/cdrh/ode/57.html (May 28, 1999)
Feldman 20 February 2003
22
In Vitro Diagnostic Devices
Feldman 20 February 2003
23
Clinical Trial Supplies for IVDs
• May need to consider both GMP and QSR regulation
• Design controls apply for device aspects
• Depending on components, may follow parts of 21 CFR 600-680 and 820
• New office in CDRH for IVDs; led by Dr. Steven Gutman
Feldman 20 February 2003
24
References
• Guideline for the manufacture of in vitro diagnostic products (Jan 10, 1994) http://www.fda.gov/cdrh/comp/918.pdf
Feldman 20 February 2003
25
FDA Inspections of Manufacturing Facilities
Feldman 20 February 2003
26
FDA Inspections
• Medical Device Quality Systems Manual, A Small Entity Compliance Guide, (Apr 14, 1999) http://www.fda.gov/cdrh/dsma/gmp_man.html
Feldman 20 February 2003
27
QSIT Approach
• Quality System Inspection Technique– 7 major systems– do CAPA and one other
• Guide to Inspections of Quality Systems Handbook (Aug 1999) http://www.fda.gov/ora/inspect_ref/igs/qsit/qsitguide.htm
Feldman 20 February 2003
28
References
• 21 CFR Parts 210, 211, 600 - 680, 820• Guidance documents
– Guide to Inspection of Quality Systems http://www.fda.gov/ora/inspect_ref/igs/qsit/qsitguide.htm
– Inspection of Medical Device Manufacturers, Final Guidance for Industry and FDA http://www.fda.gov/cdrh/comp/7382.845.html
Feldman 20 February 2003
29
More References
• Center for Drug Evaluation and Research, List of Guidance Documents (Jan 6, 2003) http://www.fda.gov/cder/guidance/guidlist.pdf– General Principles of Process Validation– Drug Master Files– Sterilization Process Validation– SUPAC (Scale-Up and Post-Approval
Changes) - several documents– etc.